CSIMarket
 
Remedent Inc   (REMI)
Other Ticker:  
 
 
Price: $0.0740 $-0.01 -6.329%
Day's High: $0.074 Week Perf: 13.85 %
Day's Low: $ 0.04 30 Day Perf:
Volume (M): 20 52 Wk High: $ 0.17
Volume (M$): $ 1 52 Wk Avg: $0.11
Open: $0.04 52 Wk Low: $0.00



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 20
 Employees 10
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 0
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Remedent Inc

We specialize in the research, development, and manufacturing of oral care and cosmetic dentistry products. We are one of the leading manufacturers of cosmetic dentistry products in Europe. Leveraging our knowledge of regulatory requirements regarding dental products and management’s experience in the needs of the professional dental community, we design, develop, manufacture and distribute our cosmetic dentistry products, including a full line of professional dental products that are distributed in Europe, Asia, Middle East and the United States.

In 2006 we developed a revolutionary system for manufacturing and installing dental veneers which we branded as GlamSmile ® veneers revolutionize the traditional one-at-a-time method of applying porcelain dental veneers. GlamSmile veneers are attached to the front of the patient’s teeth using a patent pending single motion placement tray which replaces the traditional one at a time trial and error method of applying porcelain veneers, making the application less traumatic for the patient, much easier for the dentist and perhaps most important, far less costly than traditional dental veneers. Currently, the GlamSmile veneers are our primary products in the professional oral care and cosmetic dentistry product. Our veneers are supported by a line of professional veneer whitening and teeth sensitivity solutions. Our products are sold to professionals by distributors and sold directly to consumers by our GlamSmile Studios.

We were originally incorporated under the laws of Arizona in September 1996 under the name Remedent USA, Inc. In October 1998, we were acquired by Resort World Enterprises, Inc., a Nevada corporation in a share exchange, and we immediately changed our name to Remedent USA, Inc. and later to Remedent, Inc.

In the latter part of 2008, our Board of Directors approved a strategic plan to separate our OTC business from our professional business, allowing us to focus on the development, marketing and distribution of our products for the professional dental market. In December 2008, we completed a restructuring in the form of a management-led buyout of 50% of our OTC retail business (“2008 Restructuring”). The buyout was led by Mr. Robin List, our former director and Chief Executive Officer, with financing provided by a non-affiliated foreign investment fund. In connection with the strategic plan, we effected our OTC restructuring through a series of transactions involving subsidiary formations, contributions of subsidiary(ies) interests and sales of stock interests through subsidiary transactions. As a result of the series of transactions related to the sale, Remedent Inc. retained 50% of Remedent OTC BV, a Dutch company (“Remedent OTC”) with Mr. List owning the other 50%. Remedent OTC owned and held a 75% ownership interest in Sylphar Holding BV, a Dutch holding company which owned and held the OTC operating subsidiaries (“Sylphar Holding”), together with Concordia Fund B.V. who owned 25% of Sylphar Holding. As a result of Remedent, Inc.’s ownership interest in Remedent OTC, Remedent, Inc. held an ownership interest equal to 37.5% interest in Sylphar Holding. As a result of the sale, all of the OTC business previously directly operated by us was operated and held by Sylphar Holding. In addition, following the restructuring we have focused our business primarily on the marketing and distribution of our GlamSmile Veneers.

Today, our strategic plan is to focus our vertically integrated development, manufacturing and marketing resources on selling our GlamSmile veneers direct to consumers by using all forms of direct response media including the internet, print, radio, television and social network media, to expand our presence in China and Europe. In our marketing efforts we intend to emphasize the ease, convenience, affordability and dramatic, instant results as demonstrated by before and after photos that are attained as a result of GlamSmile veneers. We will also feature our “Until You Smile” satisfaction guarantee. Using the success formula we experienced in China and Belgium using a "Smile Consultant" to help maintain control of the sales process and close the sale, our distribution will be through both owned and operated Glamsmile Studios as well as affiliations with existing dental practices and partner retail centers in Asia, Middle East and Europe.

Our current strategic marketing and distribution plan includes a combination of owned and licensed GlamSmile centers depending upon the size and location of the market, with us managing the marketing efforts, patient communications and sales process. We established two geographic divisions, Asia and Europe, each of which will promote GlamSmile veneer treatments in their respective territories. We plan to establish three types of GlamSmile Centers depending upon market factors and government regulation.

Owned Centers . These are centers in which the Company will own, control and/or manage all aspects of the operation including the facilities, equipment, personnel, marketing, insurance risk and other operating costs and will either employ or contract with dentists to perform the necessary dental services. In China, we will continue to principally rely on our owned and operated dental GlamSmile clinics or centers.

Licensed Centers . In many markets we will seek to identify and recruit cosmetic dentists that have existing practices and who endorse the GlamSmile veneer products. In these markets, we will contract with dental practices and the Company will recognize revenue through the sale of veneer trays plus marketing and other service fees to be charged to the dentist for services performed by the Company.

Distributors . In markets where we lack the expertise with respect to managing marketing and where local regulation and/or custom may make it impractical to deploy an owned or licensed center approach we will look to appoint distributors who will be granted exclusive rights to market and distribute our GlamSmile products directly to consumers subject to minimum performance criteria and/or initial territory fees. In this model the distributor will be expected to invest in all marketing and sales conversion costs in their market. Our revenues will be derived principally from sales of our GlamSmile veneer products to the distributor.

In order to support and facilitate our growth strategy, it is our intention to restructure our subsidiary companies to better manage our GlamSmile related operations. In conjunction with this restructuring, we intend to have the intellectual property and other assets related to GlamSmile contributed to a new entity to be formed to be called GlamSmile Worldwide. New entities would also be created called GlamSmile Asia and GlamSmile Europe, each with licensed rights to use and exploit the GlamSmile technology in their respective territories.

Starting in Belgium and the Netherlands, our products have been introduced utilizing our Distributor Assisted Marketing programs. We implement our program by first identifying an established dealer in each market with a well-developed sales force familiar with sales of capital equipment to the professional dentist community. Second, we develop aggressive lead generation programs and other marketing techniques which served as a blue print for the dealers to implement. The combination of a well-trained dealer force and dealer-assisted marketing and lead generation programs has proven to be far more effective than utilizing a direct sales approach, which is much slower and more costly to establish. This process has been repeated for both the professional dentist and retail, over-the-counter markets in each country. As a result of this approach, we have been able to establish dealers in 28 countries encompassing, Europe, Asia, Latin America, the Pacific Rim and the Middle East.

We previously sold our GlamSmile product in the United States and throughout the world with the exception of certain excluded territories and certain B2C markets pursuant to a distribution agreement. However, on March 27, 2012, the distribution agreements with Den-Mat were terminated pursuant to a certain Termination and Distribution Agreement with Den-Mat (“Den-Mat Distribution Agreement”). Pursuant to the Den-Mat Distribution Agreement, we granted Den-Mat a non-exclusive, irrevocable, perpetual, royalty free, license to use within certain territory, which among other territories excludes China, Macau, Hong Kong, and Taiwan, the intellectual property that was the subject of the license to Den-Mat under the Amended and Restated Distribution, License and Manufacturing Agreement dated June 3, 2009, as amended from time to time (“Prior Agreements”), as such intellectual property relates the products which was the subject of the Prior Agreements. In connection with the termination of the Prior Agreements, under the Den-Mat Distribution Agreement, Den-Mat paid us $200,000. We currently sell our products in Asia, Europe and the Middle East directly to consumers using our direct to consumer model, which includes our GlamSmile Smile Design-Virtual Studio, and GlamSmile Studios.



   


Customers Net Income grew by REMI's Customers Net Profit Margin grew to

377.27 %

1.54 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CHD        0.32% 
CL        1.33% 
CLX        3.44% 
JNJ        1.42% 
PG        0.46% 
SLGD        0.46% 
• View Complete Report
   



Prosomnus Inc

Prosomnus Inc Announces Revenue Increase to $9.345763 Million for Fiscal Year Ending December 31, 2023

ProSomnus Inc Announces Revenue Increase and Groundbreaking Development
Prosomnus Inc, a leading innovator in the field of sleep medicine, has disclosed a revenue of $9.345763 million for the fiscal span closing December 31, 2023. However, the company reported a net deficit of $-6.869 million for the same reporting season, indicating a decline compared to the previous year's zero gain.
One notable observation is the significant increase in inventories and supplies, reaching $2.0 million. This figure is higher than the preceding quarter and also higher than the corresponding quarter a year ago. This buildup in inventories can suggest positive optimism for future sales and demand for Prosomnus Inc products.
Furthermore, the company saw a notable increase in accounts receivable, which reached a value of $3.8 million compared to the preceding quarter. This rise also signals an increase in demand and is an encouraging sign for investors.

Orchestra Biomed Holdings Inc

Orchestra BioMed Holdings Inc. Achieves Significant Milestone with $0.262 Million Revenue in Q4

Orchestra BioMed Holdings, Inc. is a biomedical company that is dedicated to bringing high-impact technologies to patients through partnerships that share both the risks and rewards. Recently, the company conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension.
The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall cardiac function. The results of this pressure-volume (PV) loop study, conducted at Na Homolce Hospital in Prague under the supervision of Prof. Petr Neuil, M.D., were presented at the Technology and Heart Failure Therapeutics (THT) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg.

Delcath Systems Inc

Evanescence of Losses at Delcath Systems Inc. Signals Positive Growth in Q4 Fiscal Period 2023

Delcath Systems, Inc., a renowned interventional oncology company focusing on the treatment of primary and metastatic liver cancers, recently announced Martha S. Rook as its new Chief Operating Officer (COO). This strategic appointment is expected to enhance Delcath's operations and drive further advancements in innovative liver cancer treatments.
Martha S. Rook brings a wealth of experience to Delcath Systems, with a strong background in the healthcare and pharmaceutical industries. With her impressive track record in leadership positions, including her most recent role as Vice President of Operations at a prominent oncology therapeutics company, Rook is well-equipped to improve operational efficiency, streamline processes, and foster business growth at Delcath.

Qt Imaging Holdings Inc

QT Imaging Holdings Inc. Appoints New Leadership Team to Drive Growth and Innovation in Medical Device Industry

QT Imaging Holdings Inc. (NASDAQ: QTI) has recently undergone a significant leadership change with the appointment of Dr. Raluca Dinu as the Acting Chief Executive Officer and Anastas Budagov as the Chief Financial Officer. This move is aimed at strengthening the company's position in the medical device industry, particularly in the research, development, and commercialization of body imaging systems.
Dr. Dinu brings a wealth of experience to her new role, having previously served as the CEO of GigCapital5, Inc. Her proven track record in driving innovation and growth makes her an excellent choice to lead QT Imaging Holdings during this critical phase. Her appointment, effective from March 12, 2024, is expected to enrich the company's strategic decision-making process as she joins the Board of Directors.

Innovative Eyewear Inc

Innovative Eyewear Inc Fails to Turn Profit despite Surge in Revenue during Fourth Quarter of 2023

Innovative Eyewear Inc, a Medical Equipment and Supplies company, recently announced a significant increase in revenue for the most recent fiscal period. Despite this positive growth, the company reported a loss of $0.28 million. However, this improvement in revenue in the fourth quarter of 2023 aligns with other companies in the Medical Equipment and Supplies industry, which collectively experienced a 6.74% increase in revenue during the same period.
Compared to the previous reporting period, Innovative Eyewear Inc saw an advanced shortfall from $-0.12 per share and a doubling of revenue by 177.523%, amounting to $0.22 million. In the fourth quarter of 2023, the company reported a net shortfall of $-2.394 million, a significant improvement from the $-4.278 million deficit in the same period a year ago.






 

Remedent Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com